214 related articles for article (PubMed ID: 25537198)
1. Oxicams, a class of nonsteroidal anti-inflammatory drugs and beyond.
Xu S; Rouzer CA; Marnett LJ
IUBMB Life; 2014 Dec; 66(12):803-11. PubMed ID: 25537198
[TBL] [Abstract][Full Text] [Related]
2. Oxicams bind in a novel mode to the cyclooxygenase active site via a two-water-mediated H-bonding Network.
Xu S; Hermanson DJ; Banerjee S; Ghebreselasie K; Clayton GM; Garavito RM; Marnett LJ
J Biol Chem; 2014 Mar; 289(10):6799-6808. PubMed ID: 24425867
[TBL] [Abstract][Full Text] [Related]
3. Selective inducible microsomal prostaglandin E(2) synthase-1 (mPGES-1) inhibitors derived from an oxicam template.
Wang J; Limburg D; Carter J; Mbalaviele G; Gierse J; Vazquez M
Bioorg Med Chem Lett; 2010 Mar; 20(5):1604-9. PubMed ID: 20144869
[TBL] [Abstract][Full Text] [Related]
4. [Possibilities of individual choice of NSAIDs on the example of the oxicam class, taking into account clinical and pharmacological characteristics].
Putilina MV; Teplova NV
Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(7):36-41. PubMed ID: 35904290
[TBL] [Abstract][Full Text] [Related]
5. Microsomal prostaglandin E2 synthase: a safer target than cyclooxygenases?
Timmers L; Pasterkamp G; de Kleijn DP
Mol Interv; 2007 Aug; 7(4):195-9, 180. PubMed ID: 17827439
[TBL] [Abstract][Full Text] [Related]
6. Characterization of microsomal prostaglandin E synthase 1 inhibitors.
Korotkova M; Jakobsson PJ
Basic Clin Pharmacol Toxicol; 2014 Jan; 114(1):64-9. PubMed ID: 24138533
[TBL] [Abstract][Full Text] [Related]
7. [Development of anti-inflammatory drugs targeted against prostaglandin-related molecules].
Sato T; Nakajima T; Yamano Y
Nihon Rinsho; 2010 Oct; 68(10):1835-9. PubMed ID: 20954326
[TBL] [Abstract][Full Text] [Related]
8. Distinction of microsomal prostaglandin E synthase-1 (mPGES-1) inhibition from cyclooxygenase-2 inhibition in cells using a novel, selective mPGES-1 inhibitor.
Mbalaviele G; Pauley AM; Shaffer AF; Zweifel BS; Mathialagan S; Mnich SJ; Nemirovskiy OV; Carter J; Gierse JK; Wang JL; Vazquez ML; Moore WM; Masferrer JL
Biochem Pharmacol; 2010 May; 79(10):1445-54. PubMed ID: 20067770
[TBL] [Abstract][Full Text] [Related]
9. Enzymatic probing of model lipid membranes: phospholipase A2 activity toward monolayers modified by oxicam NSAIDs.
Czapla K; Korchowiec B; Orlof M; Magnieto JR; Rogalska E
J Phys Chem B; 2011 Jul; 115(29):9290-8. PubMed ID: 21682312
[TBL] [Abstract][Full Text] [Related]
10. [The selective inhibition of cyclooxygenase isoforms: a new approach to the search for effective and safe nonsteroidal anti-inflammatory drug agents].
Viktorov AP
Lik Sprava; 1997; (5):106-11. PubMed ID: 9491713
[TBL] [Abstract][Full Text] [Related]
11. Nonacidic inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1) identified by a multistep virtual screening protocol.
Rörsch F; Wobst I; Zettl H; Schubert-Zsilavecz M; Grösch S; Geisslinger G; Schneider G; Proschak E
J Med Chem; 2010 Jan; 53(2):911-5. PubMed ID: 20025212
[TBL] [Abstract][Full Text] [Related]
12. MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation.
Xu D; Rowland SE; Clark P; Giroux A; Côté B; Guiral S; Salem M; Ducharme Y; Friesen RW; Méthot N; Mancini J; Audoly L; Riendeau D
J Pharmacol Exp Ther; 2008 Sep; 326(3):754-63. PubMed ID: 18524979
[TBL] [Abstract][Full Text] [Related]
13. Perspective of microsomal prostaglandin E2 synthase-1 as drug target in inflammation-related disorders.
Koeberle A; Werz O
Biochem Pharmacol; 2015 Nov; 98(1):1-15. PubMed ID: 26123522
[TBL] [Abstract][Full Text] [Related]
14. Toward the management of inflammation: recent developments of mPGES-1 inhibitors.
Dallaporta M; Pecchi E; Thirion S; Jean A; Troadec JD
Recent Pat CNS Drug Discov; 2010 Jan; 5(1):70-80. PubMed ID: 19751209
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, COX-1/2 inhibition and antioxidant activities of new oxicam analogues designed as potential chemopreventive agents.
Szczęśniak-Sięga B; Gębczak K; Gębarowski T; Maniewska J
Acta Biochim Pol; 2018; 65(2):199-207. PubMed ID: 29906298
[TBL] [Abstract][Full Text] [Related]
16. Unusual coordinating behavior by three non-steroidal anti-inflammatory drugs from the oxicam family towards copper(II). Synthesis, X-ray structure for copper(II)-isoxicam, -meloxicam and -cinnoxicam-derivative complexes, and cytotoxic activity for a copper(II)-piroxicam complex.
Cini R; Tamasi G; Defazio S; Hursthouse MB
J Inorg Biochem; 2007 Aug; 101(8):1140-52. PubMed ID: 17592742
[TBL] [Abstract][Full Text] [Related]
17. Modified acidic nonsteroidal anti-inflammatory drugs as dual inhibitors of mPGES-1 and 5-LOX.
Elkady M; Nieß R; Schaible AM; Bauer J; Luderer S; Ambrosi G; Werz O; Laufer SA
J Med Chem; 2012 Oct; 55(20):8958-62. PubMed ID: 22992107
[TBL] [Abstract][Full Text] [Related]
18. Dual acting anti-inflammatory drugs: a reappraisal.
Bertolini A; Ottani A; Sandrini M
Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
[TBL] [Abstract][Full Text] [Related]
19. Prostaglandin E(2) synthase inhibition as a therapeutic target.
Iyer JP; Srivastava PK; Dev R; Dastidar SG; Ray A
Expert Opin Ther Targets; 2009 Jul; 13(7):849-65. PubMed ID: 19530988
[TBL] [Abstract][Full Text] [Related]
20. PGE synthase inhibitors as an alternative to COX-2 inhibitors.
Jachak SM
Curr Opin Investig Drugs; 2007 May; 8(5):411-5. PubMed ID: 17520870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
